We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glucagon‐like peptide‐1 receptor agonists in the era of COVID‐19: Friend or foe?
- Authors
Belančić, Andrej; Kresović, Andrea; Troskot Dijan, Marija
- Abstract
Summary: The aim of the present manuscript is to discuss on potential pros and cons of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as glucose‐lowering agents during COVID‐19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without diabetes mellitus type 2. Besides being important glucose‐lowering agents, GLP‐1RAs pose promising anti‐inflammatory and anti‐obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP‐1RAs seem to be potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose‐lowering) agents during COVID‐19 pandemic times.
- Subjects
GLUCAGON-like peptide-1 receptor; GLUCAGON-like peptide-1 agonists; COVID-19 pandemic; COVID-19; TYPE 2 diabetes
- Publication
Clinical Obesity, 2021, Vol 11, Issue 2, p1
- ISSN
1758-8103
- Publication type
Article
- DOI
10.1111/cob.12439